The current financial score of Opus Genetics Inc is 6.13. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 755.00K, representing a year-over-year decrease of 73.80%, while its net profit experienced a year-over-year decrease of 9.14%.
The current valuation score of Opus Genetics Inc is 9.02. Its current P/E ratio is -3.96, which is -266.25% below the recent high of 6.58 and -82.37% above the recent low of -7.21.
The current earnings forecast score of Opus Genetics Inc is 8.56. The average price target is 12.72, with a high of 20.00 and a low of 8.00.
The current price momentum score of Opus Genetics Inc is 7.93. Currently, the stock price is trading between the resistance level at 7.00 and the support level at 3.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Opus Genetics Inc is 3.00. The latest institutional shareholding proportion is 41.70%, representing a quarter-over-quarter increase of 43.05%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
The current risk assessment score of Opus Genetics Inc is 3.58. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.